Focused On-demand Library for Transcription initiation factor TFIID subunit 2

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6P1X5

UPID:

TAF2_HUMAN

Alternative names:

150 kDa cofactor of initiator function; RNA polymerase II TBP-associated factor subunit B; TBP-associated factor 150 kDa; Transcription initiation factor TFIID 150 kDa subunit

Alternative UPACC:

Q6P1X5; B2RE82; O43487; O43604; O60668; Q86WW7; Q8IWK4

Background:

Transcription initiation factor TFIID subunit 2, also known as TAF2, plays a pivotal role in the initiation of RNA polymerase II-dependent transcription. It is part of the TFIID complex, crucial for recognizing and binding promoters, facilitating the assembly of the pre-initiation complex. TAF2, alongside TAF7 and TAF1, forms a subcomplex essential for promoter DNA binding.

Therapeutic significance:

Understanding the role of Transcription initiation factor TFIID subunit 2 could open doors to potential therapeutic strategies, especially considering its involvement in a neurodevelopmental disorder characterized by intellectual development impairment, microcephaly, and foot deformity.